Company
Y-mAbs Therapeutics
Y-mAbs Therapeutics has 25 drugs tracked on RxWires: 1 in Phase 2/3, 7 in Phase 2, 7 in Phase 1/2, 9 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| 131I-omburtamab | Phase 2/3 | Neuroblastoma |
| Naxitamab and GM-CSF in combination with irinotecan and temozolomide | Phase 2 | Neuroblastoma Recurrent |
| Naxitamab | Phase 2 | High-Risk Neuroblastoma |
| 131 I-omburtamab | Phase 2 | Desmoplastic Small Round Cell Tumor |
| Hu3F8 | Phase 2 | Neuroblastoma |
| humanized anti-GD2 antibody | Phase 2 | Recurrent Osteosarcoma |
| Irinotecan | Phase 2 | Recurrent Medulloblastoma |
| GM-CSF + Naxitamab | Phase 2 | Neuroblastoma |
| Humanized 3F8 Bispecific Antibody | Phase 1/2 | Neuroblastoma |
| Hu3F8 With GM-CSF | Phase 1/2 | Neuroblastoma |
| adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH | Phase 1/2 | Neuroblastoma |
| Sacituzumab govitecan | Phase 1/2 | Metastatic Triple-Negative Breast Cancer |
| Nivatrotamab | Phase 1/2 | SCLC |
| 177Lu-DTPA-omburtamab | Phase 1/2 | Medulloblastoma, Childhood |
| radiolabeled DPTA-omburtamab | Phase 1/2 | Leptomeningeal Metastasis |
| Humanized 3F8 Monoclonal Antibody (Hu3F8) | Phase 1 | Neuroblastoma |
| GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi) | Phase 1 | SCLC |
| 25 mCi 177Lu- DTPA-omburtamab | Phase 1 | Recurrent Medulloblastoma |
| cyclophosphamide | Phase 1 | Neuroblastoma |
| CD38-SADA:177Lu-DOTA Complex | Phase 1 | Non-hodgkin Lymphoma |
| Radioactive iodine-labeled monoclonal antibody omburtamab | Phase 1 | Brain Cancer |
| CD33*CD3 BsAb | Phase 1 | AML, Childhood |
| Iodine I 131 MOAB 8H9 | Phase 1 | Brain and Central Nervous System Tumors |
| 131 I-8H9 | Phase 1 | Peritoneal Cancer |
| 124I-Humanized 3F8 | Not Applicable | Melanoma |
Latest
No recent events.
Follow Y-mAbs Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.